Avidia Bancorp CEO Cozzone buys $49,986 in shares
Donald A. Bergstrom, President, R&D, of Relay Therapeutics, Inc. (NASDAQ:RLAY), sold 30,897 shares of common stock on October 28, 2025, for $225239. The price per share was $7.29.
The sale was to cover income tax withholding obligations upon the vesting of restricted stock units. Following the transaction, Bergstrom directly owns 521,823 shares of Relay Therapeutics, Inc., which includes 168,866 shares underlying restricted stock units.
In other recent news, Relay Therapeutics has been the focus of analyst attention with differing perspectives on its stock. Guggenheim initiated coverage on Relay Therapeutics with a Buy rating, setting a price target of $15.00. The firm highlighted Relay’s promising oncology pipeline, particularly the RLY-2608, which is in a fully-funded Phase 3 breast cancer trial. Guggenheim also questioned why the company trades below its cash value despite these developments. Meanwhile, Wells Fargo reiterated its Equal Weight rating with a $4.00 price target. The firm noted that Relay’s shares have declined 15% year-to-date, underperforming the broader XBI biotech index. These recent developments reflect the varied analyst views on Relay Therapeutics’ potential in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.